Business Context and Reporting Period
This Form 8-K Current Report is filed by Oncocyte Corporation (trading symbol: OCX) on October 2, 2024. The filing primarily announces the entry into a material definitive agreement for a private placement of equity securities. Note: While the request metadata mentions "Insight Molecular Diagnostics Inc.", the filing text explicitly identifies the registrant as Oncocyte Corporation.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock.
- Shares Issued: 3,461,138 shares of common stock.
- Purchase Price: $2.948 per share.
- Gross Proceeds: Approximately $10.2 million (before deducting placement agent fees and expenses).
- Use of Proceeds: General corporate purposes and working capital.
- Placement Agent: Needham & Company, LLC.
- Expected Closing: On or about October 4, 2024, subject to customary conditions.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement with accredited investors. Under the Registration Rights Agreement, the Company agreed to file a registration statement with the SEC for the resale of the shares within 15 days of the agreement date, with an expectation of effectiveness within 30 days (or 45 days in the event of a full SEC review).
Guidance, Outlook, and Other Events
- New Customers: The Company announced the acquisition of two new customers: leading transplant university hospitals in the U.S. and Germany.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the transaction closing and proceeds. Management cautions that actual results may differ materially due to risks outlined in previous 10-K and 10-Q filings.
- Regulatory Status: The issuance of shares relies on exemptions from registration under Section 4(a)(2) of the Securities Act and Regulation D.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $10.2 million gross proceeds.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor the filing and effectiveness status of the registration statement for the resale of shares.
- Assess the commercial impact of the new hospital contracts mentioned in the press release (Exhibit 99.2).
- Confirm the exact net proceeds after deducting placement agent fees and offering expenses.